Philips’ investors can ill-afford another jolt to their nerves - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
飞利浦

Philips’ investors can ill-afford another jolt to their nerves

Investors in the Dutch healthcare conglomerate had until this week been enjoying a restorative patch

Some companies, it seems, receive the benefit of the doubt even if their performance is a little ho-hum. They can, for example, highlight weak Chinese demand and get away with a mere share price ripple. Other stocks take a razor-sharp cut on every lump and bump. 

Philips is a case in point. Investors in the Dutch healthcare conglomerate, which makes everything from diagnostic machines to electric shavers, had until this week been enjoying a restorative patch. Legal woes over malfunctioning sleep apnoea machines had been resolved faster and more cheaply than feared, and sales seemed to be heading in the right direction.

But a stumble has undone much of the progress. Philips’ stock has fallen 15 per cent since it released soft third-quarter results on Monday. While Italy’s Agnelli family — who made a big investment in the stock in August 2023 through their public vehicle Exor — is still in the money, this week marks a blow for those who had more recently got behind Philips’ turnaround story.

Investors must be wondering what exactly hit them. The issues Philips highlighted at third-quarter results are hardly unheard of. An anti-corruption drive at Chinese hospitals is slowing procurement of diagnostics machines — a headwind that drove guidance downgrades at rivals Siemens Healthineers and GE Healthcare after second-quarter results, points out Lisa Clive at Bernstein. And while a double-digit fall in personal care sales in China is surprising in its magnitude, the weakness of Chinese consumer demand has been widely flagged across industries.

Meanwhile, results outside China are strong. Operating margins remain healthy despite slower than expected sales. Philips does not look expensive, either. It trades on 15 times next year’s — reduced — earnings expectations despite double-digit EPS growth through to 2026, on Barclays estimates. Siemens Healthineers trades on more than 19 times.

The best explanation for the share price reaction is that Philips is suffering from sticky negative sentiment, a malady that can afflict companies that have severely spooked the market in recent history.

Curing it requires not just solving one problem, no matter how major. It requires solving all of them. That’s something that GSK, reporting on Wednesday, will be acutely aware of. Following the resolution of the Zantac heartburn medicine legal overhang, analysts are now fretting over the strength of its vaccine sales.

Traumatised investors require a long period of peace and quiet to recover their composure. Philips cannot afford another jolt to their nerves.

camilla.palladino@ft.com

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

再次陷入危机的大众汽车能走上改革之路吗?

欧洲最大的汽车制造商正与工人和政界人士交战,试图渡过痛苦的电动汽车转型期。

哈里斯的另一个大选对手:通货膨胀

美国选民对高昂生活成本的不满可能决定下周谁将赢得白宫。

Lex专栏:Meta和微软通过季度理智检查

科技巨头今天吹捧真正的胜利,以证明明天的巨额投资是合理的。投资者对此是支持的,但程度有限。

FT社评:英国工党预算——雄心勃勃,前景不明

财政大臣蕾切尔•里夫斯现在必须兑现她的投资计划,否则税收还将进一步增加。

Lex专栏:大众汽车很难走出死胡同

尽管这家汽车制造商计划裁员和关闭工厂,但投资者的担忧是可以理解的。

安谋如何成为人工智能投资热潮中的意外赢家

这家由软银控股的英国芯片设计公司的股价在过去一年上涨了两倍。但它的野心远不止于此。
设置字号×
最小
较小
默认
较大
最大
分享×